GlassScriptPhysician profile
Jacqueline N Cady
NPI 1508536285
$3,034.87
in general payments reported to CMS, 2019-2025
16 companies · $592 in 2025
The $592 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.29 · 2022: $724 · 2023: $397 · 2024: $1,263 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $702.72 | 2022-2025 | |
| Bard Peripheral Vascular, INC. | $454.61 | 2023-2024 | Lutonix Drug Coated Balloon |
| Ardelyx, INC. | $445.89 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Otsuka America Pharmaceutical, INC. | $309.40 | 2022-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $208.17 | 2022-2025 | Velphoro |
| Vifor Pharma, INC. | $198.58 | 2022-2024 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $182.57 | 2021-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $149.57 | 2022-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Aurinia Pharma U.S., INC. | $100.27 | 2022-2024 | Lupkynis |
| Travere Therapeutics, INC. | $54.18 | 2024 | |
| Akebia Therapeutics INC | $28.33 | 2021-2022 | |
| Lilly USA, LLC | $21.10 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.93 | 2024 | Jardiance |
| Scpharmaceuticals INC. | $17.32 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.23 | 2023 | Parsabiv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Cady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.